369 related articles for article (PubMed ID: 25737447)
1. MicroRNA-31 is a transcriptional target of histone deacetylase inhibitors and a regulator of cellular senescence.
Cho JH; Dimri M; Dimri GP
J Biol Chem; 2015 Apr; 290(16):10555-67. PubMed ID: 25737447
[TBL] [Abstract][Full Text] [Related]
2. A miR-200c/141-BMI1 autoregulatory loop regulates oncogenic activity of BMI1 in cancer cells.
Dimri M; Kang M; Dimri GP
Oncotarget; 2016 Jun; 7(24):36220-36234. PubMed ID: 27105531
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-16 mediates the regulation of a senescence-apoptosis switch in cutaneous T-cell and other non-Hodgkin lymphomas.
Kitadate A; Ikeda S; Teshima K; Ito M; Toyota I; Hasunuma N; Takahashi N; Miyagaki T; Sugaya M; Tagawa H
Oncogene; 2016 Jul; 35(28):3692-704. PubMed ID: 26640145
[TBL] [Abstract][Full Text] [Related]
4. Timosaponin A-III inhibits oncogenic phenotype via regulation of PcG protein BMI1 in breast cancer cells.
Gergely JE; Dorsey AE; Dimri GP; Dimri M
Mol Carcinog; 2018 Jul; 57(7):831-841. PubMed ID: 29528145
[TBL] [Abstract][Full Text] [Related]
5. microRNA-141 regulates BMI1 expression and induces senescence in human diploid fibroblasts.
Dimri M; Carroll JD; Cho JH; Dimri GP
Cell Cycle; 2013 Nov; 12(22):3537-46. PubMed ID: 24091627
[TBL] [Abstract][Full Text] [Related]
6. The polycomb group protein BMI1 is a transcriptional target of HDAC inhibitors.
Bommi PV; Dimri M; Sahasrabuddhe AA; Khandekar J; Dimri GP
Cell Cycle; 2010 Jul; 9(13):2663-73. PubMed ID: 20543557
[TBL] [Abstract][Full Text] [Related]
7. The pan-deacetylase inhibitor panobinostat suppresses the expression of oncogenic miRNAs in hepatocellular carcinoma cell lines.
Henrici A; Montalbano R; Neureiter D; Krause M; Stiewe T; Slater EP; Quint K; Ocker M; Di Fazio P
Mol Carcinog; 2015 Aug; 54(8):585-97. PubMed ID: 24375802
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase inhibitors inhibit metastasis by restoring a tumor suppressive microRNA-150 in advanced cutaneous T-cell lymphoma.
Abe F; Kitadate A; Ikeda S; Yamashita J; Nakanishi H; Takahashi N; Asaka C; Teshima K; Miyagaki T; Sugaya M; Tagawa H
Oncotarget; 2017 Jan; 8(5):7572-7585. PubMed ID: 27935859
[TBL] [Abstract][Full Text] [Related]
9. Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells.
Wang S; Huang J; Lyu H; Lee CK; Tan J; Wang J; Liu B
Cell Death Dis; 2013 Mar; 4(3):e556. PubMed ID: 23519125
[TBL] [Abstract][Full Text] [Related]
10. The epigenetic regulation of Dicer and microRNA biogenesis by Panobinostat.
Hoffend NC; Magner WJ; Tomasi TB
Epigenetics; 2017 Feb; 12(2):105-112. PubMed ID: 27935420
[TBL] [Abstract][Full Text] [Related]
11. PLK1 inhibition down-regulates polycomb group protein BMI1 via modulation of the miR-200c/141 cluster.
Dimri M; Cho JH; Kang M; Dimri GP
J Biol Chem; 2015 Jan; 290(5):3033-44. PubMed ID: 25505268
[TBL] [Abstract][Full Text] [Related]
12. DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines.
LaBonte MJ; Wilson PM; Fazzone W; Groshen S; Lenz HJ; Ladner RD
BMC Med Genomics; 2009 Nov; 2():67. PubMed ID: 19948057
[TBL] [Abstract][Full Text] [Related]
13. The ZEB1 transcription factor acts in a negative feedback loop with miR200 downstream of Ras and Rb1 to regulate Bmi1 expression.
Liu Y; Sánchez-Tilló E; Lu X; Huang L; Clem B; Telang S; Jenson AB; Cuatrecasas M; Chesney J; Postigo A; Dean DC
J Biol Chem; 2014 Feb; 289(7):4116-25. PubMed ID: 24371144
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase inhibitors increase microRNA-146a expression and enhance negative regulation of interleukin-1β signaling in osteoarthritis fibroblast-like synoviocytes.
Wang JH; Shih KS; Wu YW; Wang AW; Yang CR
Osteoarthritis Cartilage; 2013 Dec; 21(12):1987-96. PubMed ID: 24107356
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibition in colorectal cancer cells reveals competing roles for members of the oncogenic miR-17-92 cluster.
Humphreys KJ; Cobiac L; Le Leu RK; Van der Hoek MB; Michael MZ
Mol Carcinog; 2013 Jun; 52(6):459-74. PubMed ID: 22308110
[TBL] [Abstract][Full Text] [Related]
16. BMI1 and PTEN are key determinants of breast cancer therapy: A plausible therapeutic target in breast cancer.
M JR; S V
Gene; 2018 Dec; 678():302-311. PubMed ID: 30096458
[TBL] [Abstract][Full Text] [Related]
17. HTP Nutraceutical Screening for Histone Deacetylase Inhibitors and Effects of HDACis on Tumor-suppressing miRNAs by Trichostatin A and Grapeseed (Vitis vinifera) in HeLa cells.
Mazzio EA; Soliman KF
Cancer Genomics Proteomics; 2017 Jan; 14(1):17-33. PubMed ID: 28031235
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibitor prevents cell growth in Burkitt's lymphoma by regulating PI3K/Akt pathways and leads to upregulation of miR-143, miR-145, and miR-101.
Ferreira AC; Robaina MC; Rezende LM; Severino P; Klumb CE
Ann Hematol; 2014 Jun; 93(6):983-93. PubMed ID: 24577510
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of HMGA2 by the pan-deacetylase inhibitor panobinostat is dependent on hsa-let-7b expression in liver cancer cell lines.
Di Fazio P; Montalbano R; Neureiter D; Alinger B; Schmidt A; Merkel AL; Quint K; Ocker M
Exp Cell Res; 2012 Sep; 318(15):1832-43. PubMed ID: 22683924
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic roles of Bmi1 and its therapeutic inhibition by histone deacetylase inhibitor in tongue cancer.
Li Z; Wang Y; Yuan C; Zhu Y; Qiu J; Zhang W; Qi B; Wu H; Ye J; Jiang H; Yang J; Cheng J
Lab Invest; 2014 Dec; 94(12):1431-45. PubMed ID: 25286028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
